Laboratorios Farmaceuticos Rovi, S.A. ROVI.MC
Healthcare · Drug Manufacturers - Specialty & Generic · Spain · IBEX 35
Based on the available data, Laboratorios Farmaceuticos Rovi, S.A. gets an algorithmic score of 65/100. It trades at 59.70 €, with a bearish technical trend (RSI 56.4) and 27.8% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (28.6%): generates strong profit on equity.
- High net margin (24.0%): pricing power / competitive advantage.
- Low-debt balance sheet.
- Low beta (0.44): defensive profile.
Weaknesses
- Shrinking revenue (-3.1% per year).
Fundamentals
| P/E | 16.49 |
| Forward P/E | 17.78 |
| PEG | 1.26 |
| P/B | 4.36 |
| EV/EBITDA | 17.23 |
| P/S | 3.95 |
| ROE % | 28.65 |
| ROA % | 9.44 |
| Gross margin % | 64.73 |
| Operating margin % | 9.42 |
| Net margin % | 23.96 |
| Revenue growth % (y/y) | 20.00 |
| Earnings growth % (y/y) | 246.70 |
| Revenue CAGR % | -3.12 |
| Earnings CAGR % | -11.07 |
| Debt/Equity % | 15.02 |
| Current ratio | 2.05 |
| FCF yield % | 3.91 |
| Dividend yield % | 1.62 |
| Payout % | 25.83 |
Returns
| 1 month | -0.5 % |
| 3 months | +6.8 % |
| 6 months | -26.5 % |
| YTD | -4.1 % |
| 1 year | -0.7 % |
| 3 years | +15.6 % |
| 5 years | +9.4 % |
| 10 years | +507.0 % |
Risk
| 1-year volatility | 27.8 % |
| Beta | 0.44 |
| 5-year max drawdown | -50.9 % |
| Sharpe 1A | -0.02 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a Spanish company, it depends on ECB policy, the Spanish risk premium, the eurozone cycle and, if it operates in Latin America, on emerging-market currencies (BRL, MXN).
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.